Minimal Residual Disease (MRD) in Acute Myeloid Leukemia- Are we Ready for Individualized Risk Assessment Based on MRD?

Before we can use MRD as a guide of post-remission therapy in AML, we have to standardize our methods for MRD quantification and agree on the definition of MRD-positive versus MRD-negative patients.